Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M38.3Revenue (TTM) $M--Net Margin (%)--Altman Z-Score
Enterprise Value $M-0.1EPS (TTM) $--Operating Margin %--Piotroski F-Score--
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M1,600,040ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with DBV

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
Current Price Change from Average Comment Current Shares

DBV is held by these investors:

DBV: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Rapps, MichaelDirector, Director or Senior Officer of 10% Securi 2017-01-16Buy1,200$9.48152.43view
Gridley, Anthony RonaldSenior Officer 2017-01-16Sell1,800$16.9441.26view
Dinwoodie, Tyler Wayne PaulSenior Officer 2017-01-16Buy4,000$0.1713976.47view
Brown, Mark ThomasDirector 2017-01-16Sell29,300$1.361659.56view
Bebek, IvanDirector 2017-01-16Buy8,990$3.38607.99view
smith, laurie james10% Security Holder, Director, Senior Officer 2017-01-16Buy7,500$0.415736.59view
MEHR, JEFFREYSenior Officer 2017-01-13Sell50,000$27.91-14.26view
Squibb, Geoffrey WayneDirector 2017-01-13Buy267$6.27281.66view
Smith, DavidSenior Officer 2017-01-13Sell15,000$60.38-60.37view
Rowlands, William BruceDirector, Senior Officer 2017-01-13Buy20,000$0.1515853.33view

Press Releases about DBV :

Quarterly/Annual Reports about DBV:

    News about DBV:

    Articles On GuruFocus.com
    DBV Technologies Announces Completion of Blinded Period in REALISE Study of Viaskin Peanut Oct 12 2017 
    DBV Technologies to Attend Upcoming Investor Conferences Sep 01 2017 
    DBV Technologies Announces Completion of Enrollment in Phase III Extension Study of Viaskin Peanut Aug 29 2017 
    DBV Technologies Initiates Phase III Study of Viaskin Peanut in Peanut-Allergic Patients One to Thre Aug 02 2017 
    DBV Technologies Reports First Half 2017 Financial Results Jul 28 2017 
    DBV Technologies Highlights Poster Presentations on EPIT® at the 2017 EAACI Congress Jun 17 2017 
    DBV Technologies Announces Appointment of Julie O'Neill to Board of Directors Jun 15 2017 
    DBV Technologies Announces Results of its 2017 Ordinary and Extraordinary General Meeting Jun 15 2017 
    DBV Technologies to Attend Upcoming Investor Conferences Jun 01 2017 
    DBV Technologies Highlights Research Presentation of EPIT® for the Treatment of Crohn's Disease a May 08 2017 
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

    GF Chat